Reply - 06/10/16
Doi : 10.1016/j.jaci.2016.07.005
Catherine Lemiere, MD, MSc a 
, Jacques A. Pralong, MD, MSc a, b, c, André Cartier, MD a
, Jacques A. Pralong, MD, MSc a, b, c, André Cartier, MD a a Department of Chest Medicine, Hôpital du Sacré-Coeur de Montréal, University of Montreal, Montreal, Quebec, Canada
b Institute for Work and Health, Epalinges-Lausanne, Switzerland
c Division of Pulmonary Diseases, Geneva University Hospitals, Geneva, Switzerland
Le texte complet de cet article est disponible en PDF.
| Disclosure of potential conflict of interest: C. Lemiere has received grants from GlaxoSmithKline and TEVA and has received personal fees from GlaxoSmithKline, AstraZeneca, and TEVA. A. Cartier is a board member for AstraZeneca Canada and TEVA Canada, has provided expert testimony for CNESST, has received payment for lectures from Merck Frosst Canada, has received payment for manuscript preparation from UpToDate, and has received travel support from AstraZeneca. J. A. Pralong declares no relevant conflicts of interest. |
© 2016
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 138 - N° 4
P. 1239-1240 - octobre 2016 Retour au numéro
Article précédent
- Normal nonspecific bronchial reactivity excludes occupational asthma?
- Gareth I. Walters, P. Sherwood Burge, Vicky C. Moore, Alastair S. Robertson
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?